FDA has granted Breakthrough Device designation to Natera Inc.’s Signatera test for use in the post-surgical detection and quantification of circulating tumor DNA in the blood of patients previously diagnosed with certain types of cancer and in combination with certain drugs. The designation will help accelerate FDA assessment and review of Signatera as an in vitro diagnostic for use in pharmaceutical trials.
In this episode of In the Headlines, Jacquelyn Cobb, associate editor of the The Cancer Letter, and Claire Marie Porter, reporter, discuss Claire’s interview with an NCI employee who was fired just days after returning from parental leave.
